The potential for overuse of atypical thyroid diagnoses

Cancer Cytopathology

Volumn 120, Issue 2, 2012, Pages 108-110

  Henry, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CANCER RISK; CYTOPATHOLOGY; DISEASE CLASSIFICATION; FALSE NEGATIVE RESULT; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; PRIORITY JOURNAL; REVIEW; THYROID CANCER; THYROID DISEASE; EDITORIAL; NEEDLE BIOPSY; PATHOLOGY; THYROID NODULE; THYROID TUMOR;

BIOPSY, FINE-NEEDLE; HUMANS; THYROID NEOPLASMS; THYROID NODULE;

EID: 84861717124     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20191     Document Type: Review

References (16)

1. Abele JS, Levine RA. Diagnostic criteria and risk-adapted approach to indeterminate thyroid cytodiagnosis. Cancer (Cancer Cytopathol). 2010;118:415-422.
2. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36:425-437.
3. Krane JF, Nayar R, Renshaw AA. Atypical cells of undetermined significance. In: Ali SZ, Cibas ES, eds. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria and Explanatory Notes. New York: Springer; 2010:37-49.
4. Her-Juing Wu H, Rose C, Elsheikh TM. The Bethesda system for reporting thyroid cytopathology: an experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy [published online ahead of print June 16, 2011]. Diagn Cytopathol. doi: 10.1002/dc.21754.
5. Shi Y, Ding X, Klein M, et al. Thyroid fine-needle aspiration with atypia of undetermined significance: a necessary or optional category? Cancer (Cancer Cytopathol). 2009;117:298-304.
6. Renshaw AA. Should ''atypical follicular cells'' in thyroid fine-needle aspirates be subclassified? Cancer (Cancer Cytopathol). 2010;118:186-189.
7. Theoharis CG, Schofield KM, Hammers L, Udelsman R, Chhieng DC. The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution. Thyroid. 2009;19:1215-1223.
8. Jo VY, Stelow EB, Dustin SM, Hanley KZ. Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2010;134:450-456.
9. Nayar R, Ivanovic M. The indeterminate thyroid fineneedle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer (Cancer Cytopathol). 2009;117:195-202.
10. VanderLaan PA, Marqusee E, Krane JF. Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach? Am J Clin Pathol. 2011;135:770-775.
11. Krane JF, VanderLaan PA, Faquin WC, Renshaw AA. The AUS:M ratio: a proposed performance measure for reporting in the Bethesda System for thyroid cytopathology. Cancer (Cancer Cytopathol). 2012;120:111-116.
12. Cibas ES, Zou KH, Crum CP, Kuo F. Using the rate of positive high-risk HPV test results for ASC-US together with the ASC-US/SIL ratio in evaluating the performance of cytopathologists. Am J Clin Pathol. 2008;129:97-101.
13. Renshaw A. An estimate of risk of malignancy for a benign diagnosis in thyroid fine-needle aspirates. Cancer (Cancer Cytopathol). 2010;118:190-195.
14. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
15. Lubitz CC, Faquin WC, Yang J, et al. Clinical and cytological features predictive of malignancy in thyroid follicular neoplasms. Thyroid. 2010;20:25-31.
16. Bongiovanni M, Krane JF, Cibas ES, Faquin WC. The atypical thyroid fine-needle aspiration: past, present, and future [published online ahead of print July 12, 2011]. Cancer (Cancer Cytopathol). doi: 10.1002/cncy. 20178.